Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Inrebic (fedratinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

JAK2 inhibitor, FLT3 inhibitor

Related drugs:

‹

entrectinib (178)

ruxolitinib (73)

momelotinib (2)

tofacitinib (1)

FAK-JAK 2 dual Inhib (0)

flonoltinib (0)

BS-HH-002.SA (0)

quizartinib (40)

ripretinib (11)

pexidartinib (6)

›

JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	fedratinib Resistant: C3 – Early Trials fedratinib Resistant : C3	fedratinib Resistant: C3 – Early Trials fedratinib Resistant : C3
ZNF765 overexpression	Hepatocellular Cancer	ZNF765 overexpression	Hepatocellular Cancer	fedratinib Sensitive: D – Preclinical fedratinib Sensitive : D	fedratinib Sensitive: D – Preclinical fedratinib Sensitive : D